NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Subscribe To Our Newsletter & Stay Updated